Andrew R. Jordan
Plus aucun poste en cours
Fortune : 363 320 $ au 31/07/2023
Profil
Andrew R.
Jordan was the founder who founded Guilford Pharmaceuticals, Inc. in 1993 and served as EVP-Finance & Administration.
He also held former positions as Director at Spyryx Biosciences, Inc. and Gemin X Pharmaceuticals US, Inc., Chief Strategy Officer at Idera Pharmaceuticals, Inc., Chief Financial & Business Officer at Infraredx, Inc., Chief Financial Officer at KPMG LLP, and Principal at Odyssey Pharmaceuticals.
Mr. Jordan earned an MBA degree from Rutgers State University of New Jersey in 1973.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ACERAGEN, INC.
5,37% | 19/07/2023 | 451 890 ( 5,37% ) | 363 320 $ | 31/07/2023 |
Anciens postes connus de Andrew R. Jordan
| Sociétés | Poste | Fin |
|---|---|---|
Guilford Pharmaceuticals, Inc.
 Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Fondateur | 03/10/2005 |
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Corporate Officer/Principal | - |
Spyryx Biosciences, Inc.
 Spyryx Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Spyryx Biosciences, Inc. develops therapeutics for obstructive lung diseases with a particular focus on Cystic Fibrosis and chronic obstructive pulmonary disease. The company was founded by Robert Tarran in 2013 and is headquartered in Durham, NC. | Directeur/Membre du Conseil | - |
| Odyssey Pharmaceuticals | Corporate Officer/Principal | - |
KPMG LLP
 KPMG LLP Miscellaneous Commercial ServicesCommercial Services KPMG LLP engages in the provision of audit, tax, and advisory services. It serves the banking and capital markets, building, construction and real estate, consumer and retail, energy, natural resources and chemicals, financial services, government and public sector, healthcare and life sciences, industrial manufacturing, insurance, media and entertainment, private equity, technology, telecommunications, and venture capital industries. The company was founded in 1987 and is headquartered in New York, NY. | Directeur Financier/CFO | - |
Formation de Andrew R. Jordan
| Rutgers State University of New Jersey | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Infraredx, Inc.
 Infraredx, Inc. Medical SpecialtiesHealth Technology Infraredx, Inc. is a developed cardiovascular imaging devices. Its product were TVC Imaging System dual-modality intravascular imaging system with the ability to assess vessel structure and plaque composition via integrated NIRS near infrared spectroscopy lipid-core plaque LCP detection and enhanced IVUS imaging technology. The company was founded by James E. Muller in 1999 and was headquartered in Bedford, MA. | Health Technology |
Gemin X Pharmaceuticals US, Inc.
 Gemin X Pharmaceuticals US, Inc. BiotechnologyHealth Technology Gemin X Pharmaceuticals US Inc. is engaged in the development of cancer therapeutics. It offers mimetic and telomere capping programs, as well as screening, medicinal chemistry, and preclinical development services. The company was founded by Gordon C. Shore in 1998 and is headquartered in Malvern, PA. | Health Technology |
KPMG LLP
KPMG LLP Miscellaneous Commercial ServicesCommercial Services KPMG LLP engages in the provision of audit, tax, and advisory services. It serves the banking and capital markets, building, construction and real estate, consumer and retail, energy, natural resources and chemicals, financial services, government and public sector, healthcare and life sciences, industrial manufacturing, insurance, media and entertainment, private equity, technology, telecommunications, and venture capital industries. The company was founded in 1987 and is headquartered in New York, NY. | Commercial Services |
| Odyssey Pharmaceuticals | Health Technology |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Health Technology |
Spyryx Biosciences, Inc.
Spyryx Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Spyryx Biosciences, Inc. develops therapeutics for obstructive lung diseases with a particular focus on Cystic Fibrosis and chronic obstructive pulmonary disease. The company was founded by Robert Tarran in 2013 and is headquartered in Durham, NC. | Health Technology |
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Health Technology |
